Using the Boneflo System During Orthopedic and Trauma Surgery: A Prospective Multicenter Study (BoneFlo)
Analysis of the Intraoperative Use and Handling of the Boneflo Tissue Collector System in Orthopedic and Trauma Surgery
Critical bone defects, non-unions, and delayed bone healing remain major challenges in orthopedic and trauma surgery and often require bone grafting. While a patient's own bone (autograft) is considered the gold standard, its use is limited by donor-site morbidity and limited availability. Synthetic bone substitutes offer an alternative but mainly provide structural support and lack biological activity.
This prospective multicenter pilot study evaluates the safety and feasibility of using the Boneflo® Tissue Collector System to biologically activate bone substitutes during surgery. The device collects the patient's own tissue, blood, and biologically active factors directly from the surgical site using a vacuum-assisted suction system with an integrated filter. This material is then used intraoperatively to coat and bioactivate bone substitute materials.
In healing attempts, 50 patients with critical bone defects, non-unions, or impaired bone healing were treated across four centers. Various bone substitutes, including synthetic calcium phosphate materials, collagen-based scaffolds, and allografts, were used.
The primary aim of the study was to evaluate device safety, intraoperative usability, handling, and applicability for coating and activating bone substitutes. The device was evaluated by orthopedic surgeons and other medical professionals, including nurses, physician assistants, and technical assistants.
Furthermore, these data were supplemented with clinical outcome data from healing attempts, including wound healing and radiographic bone regeneration, assessed over a minimum six-month follow-up period.
調査の概要
状態
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Mülheim、ドイツ、45468
- St. Marien-Hospital Mülheim an der Ruhr
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
Patients with critical size bone defects, non-unions or delayed bone healing
Indication for bone grafting (autologous, allogeneic, or synthetic)
Age ≥ 18 years
Written informed consent obtained prior to surgery
Ability to comply with follow-up visits for at least 6 months
Exclusion Criteria:
Active local or systemic infection
Vertebral body defects (according to device instructions for use)
Active malignancy or tumor-related bone disease
Severe systemic disease affecting bone healing (e.g., autoimmune disease, immunodeficiency)
Contraindication to surgery or anesthesia
Inability or unwillingness to provide informed consent
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：基礎科学
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の：Bioactivated Bone Substitutes Using a Surgical Suction Device
Synthetic bone substitutes were intraoperatively activated using autologous tissue in patients with critical bone defects, non-unions, and delayed bone healing.
During surgery, autologous tissue, blood, and biologically active components were collected from the surgical site under vacuum conditions using an integrated filter system.
The collected material was used to coat and biologically activate bone substitutes, including calcium phosphate ceramics, collagen-based scaffolds, and allografts.
The primary focus was on safety, intraoperative usability, handling, and applicability of the device for bone substitute bioactivation.
These data were combined with clinical outcomes in healing attempts, including wound healing and radiographic bone regeneration over a six-month follow-up period.
|
During surgery, autologous tissue, blood, and biologically active components are collected from the surgical site under vacuum conditions with an integrated filter system using the BoneFlo tissue collector.
The collected autologous material is used to coat and biologically enhance bone substitutes.
Bone substitutes include calcium phosphate ceramics, collagen-based scaffolds, and allografts.
This intervention is performed intraoperatively and aims to improve the biological activity of otherwise mainly osteoconductive materials.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of device-related adverse events (% of participants)
時間枠：Up to 30 days postoperatively
|
Assessment of safety of the surgical suction device used for intraoperative bioactivation of bone substitutes, measured by the number and proportion of participants experiencing device-related adverse events, as recorded in clinical evaluation and adverse event reporting.
|
Up to 30 days postoperatively
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Surgeon-reported usability score (Likert scale)
時間枠：Immediately after the procedure
|
Assessment of device applicability and handling using a standardized surgeon questionnaire with a Likert scale rating immediately after use.
|
Immediately after the procedure
|
|
Rate of successful intraoperative bioactivation procedures
時間枠：Intraoperatively (during the index surgical procedure)
|
Assessment of intraoperative feasibility based on successful completion of the procedure as judged by the operating surgeon.
The unit of measure is the percentage of procedures (% of procedures).
|
Intraoperatively (during the index surgical procedure)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- BO/35/2025-Studie-01 (その他の識別子：Ärztekammer Niedersachsen (Ethics Committee))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。